Skip to search formSkip to main contentSkip to account menu

L 366509

Known as: L-366,509 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

PiperidinesSpiro Compounds

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Oxytocin-mediated social enrichment promotes longer telomeres and novelty seeking
The quality of social relationships is a powerful determinant of lifetime health. Here, we explored the impact of social… 
1999
1999
Role of oxytocin in the initiation of term and preterm labor in rats: changes in oxytocin receptor density and plasma oxytocin concentration and the effect of an oxytocin antagonist, L-366,509.
Highly Cited
1994
Highly Cited
1994
1-((7,7-Dimethyl-2(S)-(2(S)-amino-4-(methylsulfonyl)butyramido)bicyclo [2.2.1]-heptan-1(S)-yl)methyl)sulfonyl)-4-(2-methylphenyl)piperaz ine (L-368,899): an orally bioavailable, non-peptide oxytocin…
Modifications to the previously reported spiroindenylpiperidine camphor-sulfonamide oxytocin (OT) antagonist L-366,509 have… 
1993
1993
Identification of an orally active, nonpeptidyl oxytocin antagonist.
L-366,509, a member of a novel class of nonpeptidyl compounds, has been characterized as an orally active oxytocin (OT… 
1993
1993
Nanomolar-affinity, non-peptide oxytocin receptor antagonists.
Non-peptide antagonists of the peptide hormone oxytocin (OT) with nanomolar OT receptor affinities are described. These compounds… 
Highly Cited
1992
Highly Cited
1992
Orally active, nonpeptide oxytocin antagonists.
The first nonpeptide antagonists of the neurohypophyseal hormone, oxytocin (OT) are described. Derivatives of the… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License